video

Oncology

ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &...

In conversation with Johnson & Johnson experts at ESMO 2025, discussing T-cell-redirecting bispecific antibodies and the future of immunotherapy.

Oncology

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

Digital

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.

R&D

Interview at LSX 25 with Steffen Sebastian Bolz

A different approach to obesity treatment, with Steffen-Seba...

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

R&D

Interview at LSX 25 with Alison Fenney feature

Why Regeneron is giving away sequencing “for free”, with Ali...

Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.